UTRECHT, The Netherlands & CAMBRIDGE, England--(BUSINESS WIRE)--PanGenetics B.V. announced today that the company has received formal regulatory approval to initiate clinical evaluation of the company’s CD40 antagonist antibody, PG102. The multi-centre trial in Hungary and Serbia will recruit patients with active psoriatic arthritis, and is designed as a double blind, placebo controlled, single ascending dose study.
